| Date | Filer | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| June 19, 2019 | CFO | Form 4 | Open market or private purchase of non-derivative or derivative security | 5,000 | $1.89 | 7,298 | |
| February 23, 2007 | President, CEO | Form 4 | Open market or private purchase of non-derivative or derivative security | 7,616 | $3.46 | 7,616 | |
| June 13, 2022 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 2,500 | -- | 7,666 | |
| June 13, 2022 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 2,500 | -- | 7,666 | |
| April 13, 2010 | Interim Chief Accounting Off. | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 700 | -- | 7,700 | |
| March 23, 2011 | Director | Form 4 | Conversion of derivative security | 5,000 | $2.40 | 8,000 | |
| June 18, 2008 | VP & Chief Medical Officer | Form 4 | Open market or private purchase of non-derivative or derivative security | 3,000 | $4.10 | 8,000 | |
| November 19, 2008 | VP & Chief Medical Officer | Form 4 | Open market or private purchase of non-derivative or derivative security | 404 | $2.50 | 8,404 | |
| March 15, 2006 | VP - Operations | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 2,000 | -- | 8,534 | |
| May 26, 2011 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 8,636 | $0.12 | 8,636 | |
| October 3, 2006 | VP of Research & Development | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 5,100 | $2.44 | 9,100 | |
| March 15, 2024 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 4,500 | -- | 9,167 | |
| May 17, 2007 | President, CEO | Form 4 | Open market or private purchase of non-derivative or derivative security | 1,784 | $4.81 | 9,400 | |
| February 20, 2018 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 3,000 | $2.17 | 9,500 | |
| March 17, 2023 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 2,000 | -- | 9,666 | |
| March 17, 2023 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 2,000 | -- | 9,666 | |
| July 7, 2017 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 6,500 | $1.88 | 9,841 | |
| May 17, 2007 | President, CEO | Form 4 | Open market or private purchase of non-derivative or derivative security | 600 | $4.82 | 10,000 | |
| February 23, 2007 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 10,000 | $3.50 | 10,000 | |
| May 25, 2005 | VP of Operations | Form 4 | Open market or private purchase of non-derivative or derivative security | 10,000 | $0.39 | 10,000 | |
| February 2, 2016 | Controller | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 7,500 | $1.33 | 10,652 | |
| March 15, 2006 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 3,676 | -- | 10,676 | |
| March 23, 2011 | Controller & CAO | Form 4 | Conversion of derivative security | 3,333 | $2.40 | 11,073 | |
| December 7, 2011 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 5,000 | $2.07 | 12,000 | |
| August 15, 2018 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 2,750 | $2.41 | 12,250 |
For recent transactions, including derivative transactions, see our Section 16 SEC filings page.
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.
